Literature DB >> 16162744

Radiation therapy for the treatment of unresected stage I-II non-small cell lung cancer.

Juan P Wisnivesky1, Marcelo Bonomi, Claudia Henschke, Michael Iannuzzi, Thomas McGinn.   

Abstract

STUDY
OBJECTIVES: Radiotherapy is considered to be the standard treatment for patients with stage I or II non-small lung cancer who refuse surgery or who are not surgical candidates because of significant comorbidities. To determine whether radiotherapy benefits these patients, we compared the survival of those treated with radiation alone to those left untreated.
METHODS: Using the Surveillance, Epidemiology, and End Results registry, we identified all patients in whom histologically confirmed, stage I and II non-small cell lung cancer had been diagnosed between 1988 and 2001. Among these patients, 4,357 did not undergo surgical resection. Kaplan-Meier survival curves were compared among patients who received and who did not receive radiation therapy. We used Cox regression analysis to evaluate the effect of radiation on survival after adjusting for potential confounders.
RESULTS: The survival of patients with lung cancer who did not undergo resection and had been treated with radiation therapy was significantly better compared to the untreated patients (stage I cancer, p = 0.0001; stage II cancer, p = 0.001). The median survival time of patients with stage I disease who underwent radiotherapy was 21 months compared to 14 months for untreated patients. Stage II patients who received and did not receive radiation therapy had median survival times of 14 and 9 months, respectively. The survival of treated and untreated patients was not significantly different approximately 5 years after diagnosis (stage I disease, 15% vs 14%, respectively; stage II disease, 11% vs 10%, respectively). In multivariate analysis, radiation therapy was significantly associated with improved lung cancer survival after controlling for age, sex, race, and tumor histology.
CONCLUSIONS: These results suggest that radiotherapy is associated with improved survival in patients with unresected stage I or II non-small cell lung cancer. The observed improvement in median survival time was only 5 to 7 months, and radiotherapy did not offer the possibility of a cure.

Entities:  

Mesh:

Year:  2005        PMID: 16162744     DOI: 10.1378/chest.128.3.1461

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  44 in total

1.  Measuring the population impact of introducing stereotactic ablative radiotherapy for stage I non-small cell lung cancer in Canada.

Authors:  Alexander V Louie; George B Rodrigues; David A Palma; Suresh Senan
Journal:  Oncologist       Date:  2014-06-20

Review 2.  Is stereotactic ablative radiotherapy an alternative to surgery in operable stage I non-small cell lung cancer?

Authors:  Andrea Riccardo Filippi; Pierfrancesco Franco; Umberto Ricardi
Journal:  Rep Pract Oncol Radiother       Date:  2013-07-01

Review 3.  Alternatives to surgery in early stage disease-stereotactic body radiotherapy.

Authors:  Meredith Elana Giuliani; Andrea Bezjak
Journal:  Transl Lung Cancer Res       Date:  2013-10

4.  Stereotactic body radiation therapy as a derivative of stereotactic radiosurgery: clinically independent but with enduring common themes.

Authors:  Brian D Kavanagh
Journal:  J Clin Oncol       Date:  2014-08-11       Impact factor: 44.544

Review 5.  Alternatives to surgery for early stage non-small cell lung cancer-ready for prime time?

Authors:  Millie Das; Mohamed H K Abdelmaksoud; Billy W Loo; Nishita Kothary
Journal:  Curr Treat Options Oncol       Date:  2010-06

6.  Radiotherapy and chemotherapy for elderly patients with stage I-II unresected lung cancer.

Authors:  Juan P Wisnivesky; Marcelo Bonomi; Linda Lurslurchachai; Grace Mhango; Ethan A Halm
Journal:  Eur Respir J       Date:  2012-01-12       Impact factor: 16.671

Review 7.  Extracranial stereotactic body radiotherapy. Review of main SBRT features and indications in primary tumors.

Authors:  Carmen Rubio; Rosa Morera; Ovidio Hernando; Thomas Leroy; S Eric Lartigau
Journal:  Rep Pract Oncol Radiother       Date:  2013-11-01

8.  Progress in the Treatment and Outcomes for Early-Stage Non-Small Cell Lung Cancer.

Authors:  Jacob Y Shin; Ja Kyoung Yoon; Gaurav Marwaha
Journal:  Lung       Date:  2018-03-17       Impact factor: 2.584

Review 9.  Proton Therapy in Non-small Cell Lung Cancer.

Authors:  Shane Mesko; Daniel Gomez
Journal:  Curr Treat Options Oncol       Date:  2018-11-27

10.  Microsimulation model predicts survival benefit of radiofrequency ablation and stereotactic body radiotherapy versus radiotherapy for treating inoperable stage I non-small cell lung cancer.

Authors:  Angela C Tramontano; Lauren E Cipriano; Chung Yin Kong; Jo-Anne O Shepard; Michael Lanuti; G Scott Gazelle; Pamela M McMahon
Journal:  AJR Am J Roentgenol       Date:  2013-05       Impact factor: 3.959

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.